Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Tscan Therapeutics, Inc. (TCRX) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Tscan Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1783328.
Total stock buying since 2021: $29,800,870.
Total stock sales since 2021: $1,015,904.
Total stock option exercises since 2021: $583,941.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 2,588,794 | $3,106,552 | 0 | $0 | 0 | $0 |
| 2024 | 15,947 | $86,663 | 164,686 | $952,049 | 157,186 | $488,062 |
| 2023 | 72,027 | $267,415 | 25,400 | $63,855 | 0 | $0 |
| 2022 | 1,405,792 | $2,683,609 | 0 | $0 | 0 | $0 |
| 2021 | 1,593,434 | $23,656,631 | 0 | $0 | 48,670 | $95,879 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-05 | 2,588,794 | $3,106,552 | 0 | $0 | 0 | $0 |
| 2024-11 | 947 | $4,113 | 0 | $0 | 0 | $0 |
| 2024-09 | 5,000 | $26,450 | 0 | $0 | 0 | $0 |
| 2024-08 | 10,000 | $56,100 | 164,686 | $952,049 | 157,186 | $488,062 |
| 2023-12 | 34,147 | $167,867 | 0 | $0 | 0 | $0 |
| 2023-06 | 37,880 | $99,548 | 0 | $0 | 0 | $0 |
| 2023-05 | 0 | $0 | 25,400 | $63,855 | 0 | $0 |
| 2022-12 | 6,000 | $9,219 | 0 | $0 | 0 | $0 |
| 2022-05 | 1,384,792 | $2,623,405 | 0 | $0 | 0 | $0 |
| 2022-03 | 15,000 | $50,985 | 0 | $0 | 0 | $0 |
| 2021-12 | 0 | $0 | 0 | $0 | 48,670 | $95,879 |
| 2021-09 | 31,601 | $243,929 | 0 | $0 | 0 | $0 |
| 2021-08 | 2,500 | $22,707 | 0 | $0 | 0 | $0 |
| 2021-07 | 1,559,333 | $23,389,995 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-05-20 | Nichols Weston | Buy | 1,200,000 | 1.20 | 1,440,000 |
| 2025-05-19 | Nichols Weston | Buy | 1,388,794 | 1.20 | 1,666,552 |
| 2024-11-15 | Nichols Weston | Buy | 947 | 4.34 | 4,113 |
| 2024-09-23 | Klencke Barbara | Buy | 5,000 | 5.29 | 26,450 |
| 2024-08-26 | Klencke Barbara | Buy | 5,000 | 5.53 | 27,650 |
| 2024-08-23 | Zdraveski Zoran (See Remarks) | Sale | 164,686 | 5.78 | 952,049 |
| 2024-08-23 | Zdraveski Zoran (See Remarks) | Option Ex | 157,186 | 3.10 | 488,062 |
| 2024-08-23 | Klencke Barbara | Buy | 5,000 | 5.69 | 28,450 |
| 2023-12-19 | Barberich Timothy J | Buy | 317 | 4.97 | 1,575 |
| 2023-12-18 | Barberich Timothy J | Buy | 28,830 | 4.89 | 140,892 |
| 2023-12-14 | Klencke Barbara | Buy | 5,000 | 5.08 | 25,400 |
| 2023-06-02 | Barberich Timothy J (Director) | Buy | 37,880 | 2.63 | 99,548 |
| 2023-05-31 | Nichols Weston | Sale | 25,400 | 2.51 | 63,855 |
| 2022-12-28 | Silver Brian M. (Chief Financial Officer) | Buy | 3,158 | 1.56 | 4,942 |
| 2022-12-27 | Silver Brian M. (Chief Financial Officer) | Buy | 2,842 | 1.50 | 4,277 |
| 2022-05-18 | Southwell David P (Chief Executive Officer) | Buy | 25,000 | 3.58 | 89,625 |
| 2022-05-11 | Baker Brothers Life Sciences Lp (Director) | Buy | 25,865 | 1.99 | 51,342 |
| 2022-05-10 | Baker Brothers Life Sciences Lp (Director) | Buy | 1,333,927 | 1.86 | 2,482,438 |
| 2022-03-24 | Silver Brian M. (Chief Financial Officer) | Buy | 15,000 | 3.40 | 50,985 |
| 2021-12-23 | Southwell David P (Chief Executive Officer) | Option Ex | 48,670 | 1.97 | 95,879 |
| 2021-09-23 | Zdraveski Zoran (Chief Legal Officer) | Buy | 4,716 | 7.48 | 35,256 |
| 2021-09-21 | Silver Brian M. (Chief Financial Officer) | Buy | 5,000 | 6.32 | 31,585 |
| 2021-09-21 | Macbeath Gavin (Chief Scientific Officer) | Buy | 57 | 6.19 | 352 |
| 2021-09-20 | Macbeath Gavin (Chief Scientific Officer) | Buy | 4,943 | 6.22 | 30,745 |
| 2021-09-09 | Silver Brian M. (Chief Financial Officer) | Buy | 5,885 | 8.48 | 49,928 |
| 2021-09-08 | Southwell David P (Chief Executive Officer) | Buy | 11,000 | 8.73 | 96,063 |
| 2021-08-27 | Desmarais William (Chief Business Officer) | Buy | 2,500 | 9.08 | 22,707 |
| 2021-07-20 | Silver Brian M. (Chief Financial Officer) | Buy | 1,000 | 15.00 | 15,000 |
| 2021-07-20 | Westphal Christoph H (10% Owner) | Buy | 133,333 | 15.00 | 1,999,995 |
| 2021-07-20 | Baker Julian (Director) | Buy | 1,425,000 | 15.00 | 21,375,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of TCRX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Tscan Therapeutics, Inc. (symbol TCRX, CIK number 1783328) see the Securities and Exchange Commission (SEC) website.